Illicit Drug Analysis Using GC–IMS and Oral Fluids
Researchers from the University of Valencia have developed a gas chromatography-drift tube ion mobility spectrometry (GC–IMS) method for the analysis of illicit and psychoactive substances in oral fluids (1).
The determination of illicit drugs is needed across many industries, from toxicology reports in hospitals to traffic control or doping prevention in professional sports. Traditionally these determinations have been carried out through the analysis of urine and blood; however, each have issues associated with them. In the case of blood, the sampling procedure is quite invasive, whereas with urine there have been numerous incidents of falsification. Therefore, interest in alternative biological fluids has increased, with oral fluids emerging as one such target. The main advantages of oral fluids are the non-invasive sampling and the potential analysis of unmetabolized drugs.
Another important consideration is the technique used to analyze the oral fluids. Hyphenated mass spectrometry techniques, and especially liquid chromatography (LC)–MS/MS, have gained in popularity because of their selectivity, specificity, and sensitivity, but they require expensive instrumentation not accessible to all laboratories. Solid-phase extraction (SPE) or liquid-phase microextraction (LPME) followed by LC–MS and GC–MS are also possibilities, requiring slightly more in terms of sample preparation than the proposed method, which utilized a simple centrifugation step prior to injection.
Other limitations of GC–IMS were acknowledged by the researchers in terms of the method’s ability to identify unknown signals. There are no global available databases for the reduced ion mobility constants (K0), and therefore, for unequivocal identification, the MS spectra should be verified. This could be a major drawback to the method’s acceptance by possible end users. However, researchers also point to a recent database of K0 values that has been published with approximately 200 psychoactive compounds, including illicit and new psychoactive substances (2), which could be used to obtain preliminary information regarding unknown substances.
As such, researchers wanted to explore the possibility of utilizing GC–IMS to determine illicit and psychoactive substances in oral fluids. Amphetamine, methylone, α-PVP, ketamine, lidocaine, MPHP, cocaine, THJ-2201, and 5F-ADB were employed as model compounds in the study. The developed method was tested through the analysis of two oral fluid certified reference materials, with the obtained relative percentage errors lower than 8.4%. This indicated that the proposed GC–IMS procedure could be a reliable, selective, and sensitive technique for the determination of psychoactive substances in oral fluids.
References
- A. Denia et al., Talanta 238, 122966 (2022).
- S. Armenta, F.A. Esteve-Turrillas, and M. Alcalà, Anal. Methods 12, 1163–1181 (2020).
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
Inside the Laboratory: The Richardson Group at the University of South Carolina
November 20th 2024In this edition of “Inside the Laboratory,” Susan Richardson of the University of South Carolina discusses her laboratory’s work with using electron ionization and chemical ionization with gas chromatography–mass spectrometry (GC–MS) to detect DBPs in complex environmental matrices, and how her work advances environmental analysis.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
Infographic: Be confidently audit ready, at any time and reduce failures in pharma QC testing
November 20th 2024Discover how you can simplify the audit preparation process with data integrity dashboards that provide transparency to key actions, and seamlessly track long-term trends and patterns, helping to prevent system suitability failures before they occur with waters_connect Data Intelligence software.
Critical Role of Oligonucleotides in Drug Development Highlighted at EAS Session
November 19th 2024A Monday session at the Eastern Analytical Symposium, sponsored by the Chinese American Chromatography Association, explored key challenges and solutions for achieving more sensitive oligonucleotide analysis.
